NASDAQ: LXRXLexicon Pharmaceuticals Inc Stock
$1.60-0.01 (-0.62%)
Updated Apr 24, 2024
LXRX Price
$1.60
Fair Value Price
-$0.39
Market Cap
$393.98M
52 Week Low
$0.92
52 Week High
$3.79
P/E
-2x
P/B
4.23x
P/S
281x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.20M
Earnings
-$177.12M
Gross Margin
92.9%
Operating Margin
-13,622.76%
Profit Margin
-14,710.9%
Debt to Equity
1.46
Operating Cash Flow
-$162M
Beta
1.11
Next Earnings
Apr 30, 2024
Ex-Dividend
N/A
Next Dividend
N/A
LXRX Overview
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LXRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LXRX ($1.60) is overvalued by 509.16% relative to our estimate of its Fair Value price of -$0.39 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LXRX ($1.60) is not significantly undervalued (509.16%) relative to our estimate of its Fair Value price of -$0.39 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LXRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LXRX due diligence checks available for Premium users.
Be the first to know about important LXRX news, forecast changes, insider trades & much more!
LXRX News
Valuation
LXRX fair value
Fair Value of LXRX stock based on Discounted Cash Flow (DCF)
Price
$1.60
Fair Value
-$0.39
Undervalued by
509.16%
LXRX ($1.60) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LXRX ($1.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LXRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LXRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2x
Industry
15.69x
Market
41.27x
LXRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.23x
Industry
5.86x
LXRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LXRX's financial health
Profit margin
Revenue
$702.0k
Net Income
-$49.8M
Profit Margin
-7,087.7%
LXRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LXRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$229.4M
Liabilities
$136.3M
Debt to equity
1.46
LXRX's short-term assets ($176.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LXRX's short-term assets ($176.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LXRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LXRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$50.5M
Investing
$51.9M
Financing
-$1.0k
LXRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LXRX vs Biotech Stocks
Lexicon Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.